Journal Club: Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer-Video Recording

Video Transcription

Video Summary

In this episode of the IGCS Journal Club, Leslie Randall and Brian Slomovitz discuss the Phase 3 trial of Tisotamab Vedotin for second-to-third-line cervical cancer treatment. The trial confirms the efficacy of Tisotamab Vedotin, offering a significant improvement in overall survival when compared to chemotherapy, with a 30% decrease in the risk of death. It also demonstrated benefits in progression-free survival and response rates. While the drug's side effects, particularly ocular and neuropathic, are noted, they are considered manageable with appropriate strategies. The discussion highlights the importance of advancing treatment options for recurrent cervical cancer and acknowledges the global need for availability of such therapies. The episode concludes with a call to prioritize prevention through HPV vaccination to potentially eliminate the need for such treatments in the future.

Keywords

Tisotamab Vedotin

cervical cancer

clinical trial

treatment efficacy

HPV vaccination

side effects